Price Alert

Global Blood Therapeutics... (GBT)

NASDAQ: GBT · Real-Time Price · USD

68.49

0.01 (0.01%)

At close: Oct 04, 2022, 10:00 PM

Global Blood Therapeutics Statistics

Share Statistics

Global Blood Therapeutics has 0 shares outstanding. The number of shares has increased by 4.55% in one year.

Shares Outstanding	n/a
Shares Change (YoY)	4.55%
Shares Change (QoQ)	1.01%
Owned by Institutions (%)	n/a
Shares Floating	58.57M
Failed to Deliver (FTD) Shares	n/a
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 6.78M, so 0% of the outstanding shares have been sold short.

Short Interest	6.78M
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.69

Valuation Ratios

The PE ratio is -6.08 and the forward PE ratio is null. Global Blood Therapeutics's PEG ratio is -0.31.

PE Ratio	-6.08
Forward PE	n/a
PS Ratio	9.46
Forward PS	n/a
PB Ratio	9.38
P/FCF Ratio	-7.08
PEG Ratio	-0.31

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Global Blood Therapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.11, with a Debt / Equity ratio of 3.36.

Current Ratio	9.11
Quick Ratio	8.45
Debt / Equity	3.36
Debt / EBITDA	-2.37
Debt / FCF	-2.54
Interest Coverage	-18.57

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$426.15K
Profits Per Employee	$-663.22K
Employee Count	457
Asset Turnover	0.21
Inventory Turnover	0.06

Taxes

Income Tax	477K
Effective Tax Rate	-0.16%

Stock Price Statistics

The stock price has increased by null% in the last 52 weeks. The beta is 0.46, so Global Blood Therapeutics's price volatility has been higher than the market average.

Beta	0.46
52-Week Price Change	n/a
50-Day Moving Average	62.32
200-Day Moving Average	n/a
Relative Strength Index (RSI)	77.11
Average Volume (20 Days)	n/a

Income Statement

In the last 12 months, Global Blood Therapeutics had revenue of 194.75M and earned -303.09M in profits. Earnings per share was -4.82.

Revenue	194.75M
Gross Profit	191.43M
Operating Income	-287.15M
Net Income	-303.09M
EBITDA	-278.53M
EBIT	-286.6M
Earnings Per Share (EPS)	-4.82

Full Income Statement

Balance Sheet

The company has 684.72M in cash and 659.62M in debt, giving a net cash position of 25.1M.

Cash & Cash Equivalents	684.72M
Total Debt	659.62M
Net Cash	25.1M
Retained Earnings	-1.29B
Total Assets	n/a
Working Capital	n/a

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -256.81M and capital expenditures -3.23M, giving a free cash flow of -260.05M.

Operating Cash Flow	-256.81M
Capital Expenditures	-3.23M
Free Cash Flow	-260.05M
FCF Per Share	-4.13

Full Cash Flow Statement

Margins

Gross margin is 98.3%, with operating and profit margins of -147.44% and -155.63%.

Gross Margin	98.3%
Operating Margin	-147.44%
Pretax Margin	-155.39%
Profit Margin	-155.63%
EBITDA Margin	-143.02%
EBIT Margin	-147.44%
FCF Margin	-133.53%

Dividends & Yields

GBT does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

Currently there are no analyst rating for GBT.

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a